Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy

NCT03294109 PHASE4 COMPLETED Results posted

A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia. The following study variables will be collected postoperatively following arrival in the post-anesthesia care unit. Current and maximum intensity pain scores will be documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24 hours will be collected from the EHR and pain diary after discharge. Patient satisfaction will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing notes.

Details

Lead sponsor	University of California, Los Angeles
Phase	PHASE4
Status	COMPLETED
Enrolment	146
Start date	Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pain, Postoperative
• Analgesics, Opioid
• Analgesics, Non-Narcotic
• Physiological Effects of Drugs
• Peripheral Nervous System Agents
• Patient Satisfaction
• Return to Work
• Activity, Sexual

Interventions

• Abdominal wall block with liposomal bupivicaine

Countries

United States